Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13431MR)

This product GTTS-WQ13431MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13431MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13021MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ4285MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ10836MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ3016MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ2942MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ9000MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ14685MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ9605MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW